

*Full Length Research Paper*

# Evaluation of different methods for the rapid diagnosis of methicillin-resistance in *Staphylococcus aureus*

Sadaka S. M., El-Ghazzawy E. F., Harfoush R. A.\* and Meheissen M. A.

Department of Medical Microbiology and Immunology, Faculty of Medicine, Alexandria University, Egypt.

Accepted 29 January, 2009

Since its first identification in the early 1960s, Methicillin-Resistant *Staphylococcus aureus* (MRSA) has been recognized as a major human pathogen. The aim of this study was to identify the prevalence of MRSA in Alexandria Main University Hospital and to settle on a simple, rapid, accurate and cost-effective phenotypic test for the detection of MRSA from clinical specimens. One hundred *S. aureus* isolates, including 71 MRSA isolates, as confirmed by PCR for the presence or absence of the *mecA* gene as the gold standard, were isolated from patients from different departments at Alexandria Main University Hospital over a six month-period. They were tested for methicillin resistance by comparing five phenotypic tests (Mannitol salt agar-cefoxitin [MSA-FOX], oxacillin disc diffusion, cefoxitin disc diffusion, oxacillin MIC by broth microdilution and latex agglutination for PBP2a) to the gold standard genotypic test (detection of *mecA* gene by PCR). It was found that both oxacillin disc diffusion and latex agglutination showed 100% sensitivity, negative and positive predictive values of 100 and 97.3%, respectively. Both were found to be highly sensitive phenotypic tests for the detection of MRSA. However, the oxacillin disc diffusion test is much more cost-effective. The MSA-FOX, whose sensitivity was 95.8%, was found to be a highly sensitive, cost-effective screening medium for the detection of MRSA.

**Key words:** *Staphylococcus aureus*, MRSA, methicillin resistance, oxacillin resistance.

## INTRODUCTION

*Staphylococcus aureus* has long been recognized as a major human pathogen responsible for a wide range of infections, from mild skin infections to wound infections and bacteraemia. Although the introduction of antibiotics has lowered the mortality rate from *S. aureus* infections, the bacteria have developed resistance mechanisms to all antimicrobial agents that have been produced (Hardy et al., 2004).

In 1960, the year methicillin was developed, the first isolation of methicillin-resistant *S. aureus* (MRSA) was reported (Jevons, 1961). MRSA is a specific strain of the *S. aureus* bacterium, which is intrinsically insensitive to methicillin and all  $\beta$ -lactams. Later use of oxacillin as an alternative to methicillin in susceptibility tests resulted in the term 'oxacillin-resistant *S. aureus*' (ORSA). These designations are used interchangeably in the literature

and are synonymous (Brown et al., 2005). Since 1961, successive waves of epidemic MRSA have spread throughout hospitals and other chronic healthcare facilities worldwide, to the extent that it is now the most commonly isolated antimicrobial-resistant pathogen in many countries (Diekema et al., 2004; Goosens 2004). Over the last few years, reports have documented an increase in community-acquired MRSA (CA-MRSA) in patients with or without risk factors for MRSA infection, which may suggest a changing epidemiology (Chambers, 2001).

The mechanism of methicillin resistance is an altered penicillin-binding protein (PBP2a) in MRSA that markedly reduces affinity for all available  $\beta$ -lactam antibiotics, while maintaining effective cell wall-building activity (Hartman and Tomasz, 1981). PBP2a is encoded by the *mecA* gene that is carried on a mobile DNA element, the staphylococcal cassette chromosome *mec* (SCC*mec*) (Katayama et al., 2000).

Timely detection of MRSA is still problematic with the majority of techniques taking longer than 48 h to produce

---

\*Corresponding author. E-mail: rim94alex@yahoo.com.  
Tel.: 00203-4861526. Fax: 00203-4873076.

a result (Hardy et al., 2004). The accurate rapid diagnosis of MRSA in microbiology laboratories is vital for patients' management. It is also essential for meaningful interpretation of surveillance data. Currently, surveillance data for MRSA is difficult to interpret because there is no uniform testing method for the detection of MRSA, and laboratories vary in their standard operating procedures and interpretation of breakpoint values (Krishanan et al., 2002).

Accurate routine phenotypic detection of MRSA is difficult using standard microbiological methods such as disc diffusion, minimal inhibitory concentration (MIC) determination, agar screening and methods that detect PBP2a. This has been ascribed to the heterogeneous methicillin resistance in most strains of MRSA where only a few cells within the total population of cells express resistance, while the majority of cells do not (Hartman and Tomasz, 1984; Hackbarth and Chambers, 1989; Chambers, 1997). No phenotypic test is completely reliable for detection of MRSA (Skulnick et al., 1992). Therefore, detection of the *mecA* gene is considered the gold standard (Chambers, 1997). Perhaps, the best phenotypic approach would be to have several methods available, and use an alternate test when resistance is suspected but not detected by the routine method (Swenson et al., 2001).

Although the vast majority of infections caused by *S. aureus* result in asymptomatic carriage, this species nevertheless represents a serious public health burden, particularly in the hospital setting, where clones resistant to methicillin and other classes of antibiotics are endemic, and insensitivity to vancomycin is on the increase (Feil et al., 2003).

The objectives of the present study were to detect the prevalence of MRSA in clinical specimens delivered to the laboratory of the Microbiology Department at Alexandria Main University Hospital, to evaluate the different phenotypic methods for the detection of MRSA with the aim of settling on a rapid, sensitive, specific, cost-effective and easily applicable method for MRSA detection in the routine Microbiology laboratory, and to compare the phenotypic methods with a molecular diagnostic assay (PCR for *mecA* gene) for confirmation.

## MATERIALS AND METHODS

### Specimen collection and processing

The materials of this study included 2,900 clinical specimens delivered to the routine laboratory of the Microbiology Department at Alexandria Main University Hospital (AMUH), over a six month-period, starting from the first of June 2006 till the end of November 2006. The specimens included swabs from surgical wounds, bed sores, pus, pleural and ascitic fluid, endotracheal and bronchial aspirates, sputum, urine, cerebrospinal fluid, as well as blood samples for blood culture. Only one clinical specimen was obtained from each patient. Each clinical specimen was inoculated onto both Columbia blood agar (Oxoid) and MacConkey's agar plates (Oxoid) and incubated at 37°C for 24 - 48 h aerobically. For the blood culture, 10 ml of the blood sample was inoculated into the blood cul-

ture bottle (Egyptian Diagnostic), which was subcultured on the same above-mentioned media after 24 and 48 h before discarding (usually seven days). After plating the specimens on the aforementioned media, they were also suspended in 5 ml phosphate buffered saline (Oxoid), then 1 µl of the resulting suspension was inoculated onto MSA-FOX mannitol salt agar (Biolife) supplemented with 4 mg/l cefoxitin (Sigma-Aldrich, Germany). One µl of the urine samples was directly inoculated on MSA-FOX; also 1 µl from the blood culture bottles was subcultured on MSA-FOX after 24, 48 h and seven days. Incubation of MSA-FOX was done for 48 h at 35°C (Perry et al., 2004; Smyth and Khlmeter, 2005; Stoakes et al., 2006).

All suspected *S. aureus* colonies on Columbia blood agar, and suspected mannitol-fermenting yellow colonies grown on MSA-FOX (MRSA) and *S. aureus* colonies that grew on blood agar and did not show growth on MSA-FOX, were identified on the following bases: Gram-stained film, positive catalase test, positive tube coagulase test and mannitol fermentation (Baird, 1996). Also, yellow colonies other than *S. aureus* grown on MSA-FOX were identified and included in the study. All other isolated strains (non-staphylococcal) were presumptively identified based on colonial morphology and the results of standard routine laboratory tests (Baird, 1996). Fully identified *S. aureus* colonies on Columbia blood agar and yellow colonies on MSA-FOX, which were confirmed to be *S. aureus*, were subjected to the following tests:

**Oxacillin disc susceptibility testing;** was performed according to CLSI recommendations using a 1 µg oxacillin disc.

**Cefoxitin disc susceptibility testing:** This was performed according to the CLSI recommendations using a 30 µg cefoxitin disc (Oxoid). Two control strains were used for quality control of the disc diffusion test, that is, a standard Methicillin sensitive *S. aureus* (MSSA) strain (ATCC 25923), and a MRSA strain (ATCC 43300).


**Oxacillin MICs.** This was determined by microdilution with Müller-Hinton broth supplemented with 2% NaCl, following the CLSI criteria. A standard MSSA strain (ATCC 29213) was used for quality control.

**Latex agglutination.** The *mecA* product (PBP2a) was detected using the Slidex MRSA kit (Biomérieux, Marcy L'Etoile, France). The method was used according to the manufacturer's instructions. A standard *mecA*-negative *S. aureus* strain (ATCC 25923), as well as a *mecA*-positive strain (ATCC 43300) were used for quality control.

**Detection of the *mecA* gene by PCR;** DNA extraction from bacteria was performed by the method described by Schmitz et al. (1998). The supernatant was used as a template in the PCR reaction. PCR reaction was performed in a 25 µl reaction volume. The oligonucleotide primers (Geno-Mechanix) were designed to amplify the 310-base pairs (bp) fragment of the *mecA* gene (Vannuffel et al., 1995). The primer sequences were as follows: forward primer (5'- TGG CTA TCG TGT CAC AAT CG -3') and reverse primer (5'- CTG GAA CTT GTT GAG CAG AG-3'). The conditions of the amplification reaction were: an initial denaturation step at 95°C for 5 min, 35 amplification cycles of denaturation at 95°C for 30 s, annealing at 56°C for 30 s, extension at 72°C for 30 s, followed by a final cycle of extension at 72°C for 3 min.

### Antibiotic susceptibility testing

Antibiotic susceptibility testing was evaluated by using penicillin (10 units), amoxicillin-clavulanic acid (20/10 µg), cephadrine (30 µg), ceftriaxone (30 µg), cefepime (30 µg), imipenem (10 µg), gentamycin (10 µg), erythromycin (15 µg), tetracycline (30 µg), ciprofloxacin (5 µg), clindamycin (2 µg), trimethoprim-sulfamethoxazole (1.25/23.75 µg), chloramphenicol (30 µg), rifampin (5 µg), fusidic acid (10 µg), and vancomycin (30 µg) (Oxoid). Zone diameters were measured fol-



**Figure 1.** Agarose gel stained with ethidium bromide of few MRSA isolates. A single band of amplified PCR product of *mecA* gene of 310 bp at lanes 2, 4, 5 and 6. Lane 1; 100 bp DNA ladder; lane 7, negative control; lane 8, positive control.

lowing the National Committee for Clinical Laboratory Standards (NCCLS) criteria (Katayama et al., 2000). Multiresistance was defined as an isolate with resistance to three or more drug classes other than  $\beta$ -lactam antibiotics.

### Statistics

Data were fed to SPSS/Win. Analysis of data was done using count, percentage, sensitivity, specificity, positive predictive value and negative predictive value.

## RESULTS

Culture-positive specimens (confirmed nosocomial pathogens) constituted 63.2% (1,833 specimens) out of the total 2,900 clinical specimens. Staphylococcus species were isolated from 203 clinical specimens, representing 11.1% (103 coagulase-negative staphylococci [CONS] representing 5.6% and 100 *S. aureus* representing 5.5%), and non-staphylococcal organisms from 1,630 clinical specimens, representing 88.9%. Among the 2,900 clinical specimens, 827 specimens showed no growth, and 240 grew mixed normal flora. *S. aureus* was mostly isolated from pus specimens (34%) and rarely from pleural fluid (2%). The highest percentage of isolates was from Intensive Care Units (ICUs) (34%).

The 2,900 clinical specimens were tested on MSA-FOX. A total of 125 specimens allowed the growth of yellow colonies on the medium when incubated at 35°C for 48 h. Among the 125 yellow colonies, 75 (60%) were found to be *S. aureus*, 4 (3.2%) were CONS and 46 (36.8%) were non-staphylococcal colonies (27 *Klebsiella* spp., 10 *Enterococcus* spp. and 9 *Diphtheroids*).

Out of 100 *S. aureus* isolates included in the study, 71 were found to be *mecA*-positive (MRSA) and 29 were found to be *mecA*-negative (MSSA) by PCR. Presence or absence of the *mecA* gene was considered the reference

method for detection of MRSA (Figure 1). Accordingly, among the confirmed 1 833 nosocomial pathogens, 3.9% were found to be MRSA.

The results of all phenotypic tests in comparison to *mecA* gene detection by PCR (the gold standard) revealed that the oxacillin disc diffusion test, as well as the latex agglutination test identified all *mecA*-positive isolates. No phenotypic test identified all *mecA*-negative isolates (Table 1).

According to the confirmed results of PCR, 71 isolates were *mecA*-positive and 29 isolates were *mecA*-negative. MSA-FOX detected 66 MRSA isolates after a 24 h incubation (93% sensitivity). It detected two additional MRSA isolates after extending the incubation to 48 h, raising the sensitivity to 95.8%. Three MRSA isolates failed to grow on MSA-FOX and were confirmed to be MRSA when isolated from conventional blood agar. As regards MSSA, MSA-FOX inhibited the growth of all but seven MSSA isolates. The specificity of the test medium was 75.9% at 24 and 48 h. After a 48 h incubation, the positive predictive value (PPV) and the negative predictive value (NPV) were 90.7% and 88%, respectively.

As regards the oxacillin disc diffusion test, the diameter of zone of inhibition was measured as follows: Susceptible ( $\geq 13$  mm), Intermediate (11 - 12 mm) and Resistant ( $\leq 13$  mm). Any growth within the zone of inhibition was an indication of oxacillin resistance.

All 71 *mecA*-positive isolates were correctly identified as oxacillin resistant by oxacillin disc diffusion, resulting in 100% sensitivity. The oxacillin disc diffusion test identified 27 *mecA*-negative isolates as oxacillin susceptible, resulting in 93.1% specificity. Therefore, the test had a PPV of 97.3% and a NPV of 100%.

In the cefoxitin disc susceptibility tests, the interpretation of inhibition zone diameters was as follows: Resistant ( $\leq 19$  mm), Sensitive ( $\geq 20$  mm). It detected oxacillin resistance correctly in all *mecA*-positive isolates, except one isolate, which gave a zone diameter of 35 mm, resulting in a sensitivity of 98.6%. As regards the *mecA*-negative isolates, the cefoxitin disc diffusion test identified eight of the isolates as oxacillin resistant. This resulted in 72.4% specificity. The test had a PPV of 89.7% and a NPV of 95.5%.

As regards the broth microdilution, equivalent MIC breakpoints for *S. aureus* were Resistant ( $\geq 4$   $\mu\text{g/ml}$ ), Sensitive ( $\leq 2$   $\mu\text{g/ml}$ ). Out of 29 *mecA* negative isolates, 28 isolates had an oxacillin MIC of  $\leq 2$   $\mu\text{g/ml}$ . This provides the test with 96.6% specificity. Out of the 71 *mecA*-positive isolates, 66 isolates had an oxacillin MIC of  $\geq 4$   $\mu\text{g/ml}$ . The remaining five isolates had an oxacillin MIC of  $\leq 2$   $\mu\text{g/ml}$ . The sensitivity of the test in relation to PCR was 93%. The test had a PPV of 98.5% and a NPV of 84.8%.

Considering PCR as a gold standard test for MRSA detection, the latex agglutination test demonstrated 100% sensitivity, 93.1% specificity, 97.3% PPV and 100% NPV. Out of the 71 *mecA*-positive isolates, 63 isolates were

**Table 1.** Results of all phenotypic tests in comparison to PCR for the 100 *S. aureus* isolates.

| Phenotypic Tests    | mecA +ve (n = 71) |           | mecA -ve (n = 29) |           | Sensitivity (%) | Specificity (%) | PPV <sup>d</sup> | NPV <sup>e</sup> |
|---------------------|-------------------|-----------|-------------------|-----------|-----------------|-----------------|------------------|------------------|
|                     | True +ve          | False -ve | True -ve          | False +ve |                 |                 |                  |                  |
| MSA-FOX             | 68                | 3         | 22                | 7         | 95.8            | 75.9            | 90.7             | 88               |
| OX DD <sup>a</sup>  | 71                | 0         | 27                | 2         | 100             | 93.1            | 97.3             | 100              |
| FOX DD <sup>b</sup> | 70                | 1         | 21                | 8         | 98.6            | 72.4            | 89.7             | 95.5             |
| OX MIC <sup>c</sup> | 66                | 5         | 28                | 1         | 93              | 96.6            | 98.5             | 84.8             |
| Latex               | 71                | 0         | 27                | 2         | 100             | 93.1            | 97.3             | 100              |

a, OX DD: oxacillin disc diffusion; b, FOX DD: ceftioxin disc diffusion; c, OX MIC: oxacillin MIC by broth microdilution method; d, PPV: positive predictive value; e, NPV: negative predictive value.

**Table 2.** Antimicrobial susceptibility testing results of the 71 MRSA isolates.

| Antibiotic                    | MRSA (n = 71) |      |
|-------------------------------|---------------|------|
|                               | Resistance    |      |
|                               | No.           | %    |
| Penicillin                    | 71            | 100  |
| Amoxicillin- Clavulanic acid  | 55            | 77.5 |
| Cephadrine                    | 64            | 90.2 |
| Ceftriaxone                   | 66            | 93   |
| Cefepime                      | 69            | 97.2 |
| Imipinem                      | 43            | 60.6 |
| Erythromycin                  | 38            | 53.5 |
| Gentamycin                    | 55            | 77.5 |
| Tetracycline                  | 56            | 78.8 |
| Clindamycin                   | 17            | 24   |
| Chloramphenicol               | 17            | 24   |
| Rifampin                      | 13            | 18.3 |
| Ciprofloxacin                 | 53            | 74.6 |
| Trimethoprim-Sulfamethoxazole | 25            | 35.2 |
| Fusidic acid                  | 17            | 24   |
| Vancomycin                    | 0             | 0    |

oxacillin resistant in all phenotypic tests used in the study, while eight mecA-positive isolates showed discrepant results in one or more phenotypic tests. Three isolates did not grow on MSA-FOX (after 48 h), four were sensitive to oxacillin in the broth microdilution test (their MIC values < 2 µg/ml), and one had an oxacillin MIC of 2 µg/ml and 35 mm zone diameter with the ceftioxin disc. On the other hand, out of the 29 mecA-negative isolates, 17 isolates were oxacillin sensitive in all tests, while 12 isolates showed discrepant results. Four grew on MSA-FOX after 24 h of incubation, five isolates were resistant to the ceftioxin disc (zone diameter < 15 mm), one grew on MSA-FOX and was also resistant to the ceftioxin disc (with a zone diameter of 10 mm), one isolate was resistant to oxacillin in all phenotypic tests and one isolate

was oxacillin resistant in all tests except for a sensitive MIC (2 µg/ml).

Concerning the distribution of MRSA among the different clinical specimens, sputum was the most frequent specimen from which MRSA was isolated (28 isolates representing 39.4%), 19 isolates (26.8%) were isolated from pus, 12 isolates (16.9%) from blood, eight isolates (11.3%) from wound swabs, three isolates (4.2%) from bed sore swabs and only one isolate (1.4%) from pleural fluid.

Regarding the hospital sites from which MRSA was detected, the ICU was the most common site from which MRSA was isolated (28 isolates representing 39.4%) followed by the Emergency Unit where nine isolates (12.7%) were isolated. Six isolates (8.5%) were isolated from each of the following departments, Surgery, Internal Medicine, and Dermatology, four isolates (5.6%) from Chest, three isolates (4.2%) from each of Cardiothoracic Surgery, and Oncology, two isolates (2.8%) from the Gangrene Unit and one isolate (1.4%) from each of the following departments, Neurology, Cardiology, Urology and the Burn Unit.

As regards the antibiotic susceptibility to 16 antibiotics (other than oxacillin and ceftioxin), all MRSA isolates were sensitive to vancomycin and resistant to penicillin. The resistance to β-lactam drugs varied; cefepime (97.2%), ceftriaxone (93%), cephadrine (90.2%), amoxicillin-clavulanic acid (77.5%) and imipinem (60.6%). The resistance to non-β lactam drugs ranged from 78.8% for tetracycline to 18.3% for rifampin. Multi-drug resistant MRSA accounted for 83% of MRSA isolates (Table 2).

## DISCUSSION

MRSA is probably the most challenging bacterial pathogen that currently affects patients in hospital and in the community (Rayner, 2003). Methicillin resistance renders *S. aureus* resistant to all β-lactam antibiotics, the most important group of antibiotics in the treatment of staphylococcal infections. Accurate and rapid detection of methicillin resistance in staphylococci is therefore important, not only for choosing appropriate antibiotic therapy for the

individual patient, but also for control of the endemicity of MRSA (Skov et al., 2003). Although multiple methods of detection of methicillin resistance have been developed, identification of the *mecA* gene is the most reliable reference method of detecting MRSA isolates (Velasco et al., 2005). This study was carried out aiming to settle on a rapid, reliable, cost-effective and easily applicable method for MRSA detection in the routine Microbiology laboratory.

*S. aureus* isolates in our study constituted 5.5% (100 out of 2 900 isolates) of nosocomial pathogens. This low percentage of *S. aureus* as compared to the study of Savas et al. (2005), where *S. aureus* was isolated from 39.6% of 871 various clinical specimens, and the study of El-Farrash et al. (2003), where 370 *S. aureus* isolates (17.2%) were identified, could be attributed to the large number of randomly collected specimens from different departments of the hospital with no selection of high risk patients.

Among the 100 *S. aureus* isolates identified in the present study, 71 (71%) were found to be MRSA constituting 3.9% of nosocomial pathogens, in accordance with the study conducted by APIC (Association for Professionals in Infection and Epidemiology) (2007) on the prevalence of MRSA in U.S. healthcare facilities that showed that 3.4% of patients were infected with MRSA and that it accounts for as many as 50 - 70% of the *S. aureus* infections acquired in healthcare facilities.

On the other hand, the prevalence of MRSA among *S. aureus* in the present study was higher than that reported by Akpaka et al. (2006) 12.8%, Ontengco et al. (2004) 18% and El-Farrash et al. (2003) 24.6%. The high prevalence of MRSA in the present study may reflect the inappropriate use of antibiotics, as well as a compromise in infection control policies.

It is also evident that the prevalence of MRSA among *S. aureus* isolates in our hospital has increased from 32% in 1989, as stated by Zaki et al. (1989), to 71% as reported in the present study. This probably signifies the emergence of MRSA as a common nosocomial pathogen in AMUH. This finding was consistent with data from the National Nosocomial Infections Surveillance NNIS System (USA), according to which the prevalence of MRSA among hospitalized patients increased from 31.9% in 1996 to 60.7% in 2004.

In the present study, MSA supplemented with 4 µg/ml cefoxitin (MSA-FOX) was evaluated as a screening medium for the detection of MRSA directly from clinical specimens. Failure of the three MRSA isolates to grow on MSA-FOX may be due to sensitivity to the selective agents in the medium base and/or the low number of organisms present in the inoculum. On the other hand, the growth of the seven MSSA isolates on MSA-FOX may be contributed to degradation of cefoxitin in the medium.

Smyth and Kahlmeter (2005) also stated that mannitol salt cefoxitin medium was superior to screening media

containing oxacillin because the majority of the strains tested produced visible colonies after 18 h of incubation and the shelf-life of the medium is 30 days at a temperature of 2 - 8°C. In contrast, selective media containing oxacillin deteriorate after one week.

In this study, the 1 µg oxacillin disc diffusion test correctly identified all the 71 *mecA*-positive (MRSA) and 27 *mecA*-negative (MSSA) strains in accordance with the study conducted by Fawzi et al. (2007), where the oxacillin disc diffusion test showed 100% sensitivity and 95.6% specificity.

Regarding cefoxitin disc diffusion, several groups of investigators have reported that the results of cefoxitin disc diffusion tests correlate better with the presence of *mecA* than do the results of disc diffusion tests using oxacillin (Felten et al., 2002; Boutiba et al., 2004; Cauwelier et al., 2004 and Swenson and Tenover, 2005).

In the present study, the 30 µg cefoxitin disc diffusion identified 70 out of 71 MRSA isolates. The same finding was reported by Kircher et al. (2004), who found that one MRSA isolate out of 203 tested MRSA strains produced a zone diameter of 24 mm. This isolate also had an MIC to oxacillin of 2 µg/ml.

In the present study, the broth microdilution test detected 66 out of 71 MRSA isolates and 28 out of 29 MSSA isolates. Failure of the broth microdilution method to detect five MRSA isolates may be attributed to the heterogeneous resistance of MRSA.

The latex agglutination test in the present study was easy to perform, gave results rapidly and was amenable to the processing of a large number of samples. The use of a larger inoculum or induction by a β-lactam was not needed. This is in agreement with other studies that have evaluated the latex agglutination test, which showed sensitivity without β-lactam induction ranging from 93.5 to 100% and specificity ranging from 96.9 to 100% (Nakatomi and Sugiyama, 1998; Van Griethaysen et al., 1999; Cavassini et al., 1999; Sakoulas et al., 2001).

In the present study, in a PCR reaction, 71 *mecA*-positive strains and 29 *mecA*-negative strains were identified. However, two *mecA*-negative strains were confirmed to be MRSA by most phenotypic tests. This finding may be due to point mutation or deletion in the *mecA* gene, or other mechanisms of oxacillin resistance such as hyperproduction of β-lactamase, which was not assessed in our study, or modified PBPs. Our results were in accordance with that of Warren et al. (2004), who found three *mecA*-negative isolates phenotypically resistant when grown on oxacillin screen agar, suggesting that methicillin resistance in these isolates was mediated by methods other than PBP2a, such as hyperproduction of β-lactamase or modified PBPs.

The antibiogram of MRSA isolates in the present study was in agreement with the studies of Tai et al. (2006) and Anbumani et al. (2006). However, the resistance to gentamycin in this study was higher than that reported in the studies of Zaki et al. (1989) and El-Hefnawy (1993). Inte-

restingly, among the tested  $\beta$ -lactam drugs in our study, cefepime and ceftriaxone gave the best indication of oxacillin resistance when both intermediate and resistant zone diameters were considered as clues for oxacillin resistance, as recommended by CLSI.

In conclusion, no single phenotypic test is completely reliable for the detection of oxacillin resistance in *S. aureus*. A cost-effective option in most laboratories would be to adopt a well standardized phenotypic technique with stringent quality control measures for day-to-day testing, and to retest ambiguous results with a second conventional phenotypic method. It was found that MSA-FOX is a good, cost-effective screening medium for the detection of MRSA from clinical specimens, as well as MRSA carriage in healthcare personnel after 24 h in a single step. Also, the oxacillin disc diffusion test and the latex agglutination test are the best tests for identification of MRSA. Isolates that give inconsistent results with two different conventional tests could then be tested with the latex agglutination test and sent to a reference laboratory for *mecA* detection. Vancomycin is still the drug of choice for treatment of MRSA; however, regular monitoring of vancomycin sensitivity should be carried out.

## REFERENCES

- Akpaka PE, Kissoon S, Swanston WH, Monteil M (2006). Prevalence and antimicrobial susceptibility pattern of methicillin resistant *Staphylococcus aureus* isolates from Trinidad & Tobago. *Ann. Clin. Microbiol. Antimicrob.* 5: 16-21.
- Anbumani N, Wilson AA, Kalyani J, Mallika M (2006). Prevalence of methicillin-resistant *Staphylococcus aureus* in a Tertiary Referral Hospital in Chennai, South India. *Ind. J. Pract. Doc.* 3: 8-9.
- Association for Professionals in Infection and Epidemiology (APIC), (2007). National prevalence study of methicillin-resistant *Staphylococcus aureus* (MRSA) in U.S. healthcare facilities (executive summary).
- Baird D (1996). *Staphylococcus*: Cluster-forming gram-positive cocci. In: Collee JG et al. (eds) Mackie and McCartney Practical Medical Microbiology (14th ed) Churchill Livingstone, New York, pp: 245-258.
- Boutiba-Ben Boubaker I, Ben Abbes R, Ben Abdallah H, Mamlouk Kand Mahjoubi F (2004). Evaluation of a cefoxitin disc diffusion test for the routine detection of methicillin resistant *Staphylococcus aureus*. *Clin. Microbiol. Infect.* 10: 762-765.
- Brown DF, Edwards DI, Hawkey EM, Morrison D, Ridgway GL (2005). Guidelines for the laboratory diagnosis and susceptibility testing of methicillin resistant *Staphylococcus aureus*. *J. Antimicrob. Chemother.* 56: 1000-1018.
- Cauwelier B, Gordts B, Descheemaeker P, Van Landuyt H (2004). Evaluation of a disc diffusion method with cefoxitin (30  $\mu$ g) for detection of methicillin-resistant *Staphylococcus aureus*. *Eur. J. Clin. Microbiol. Infect. Dis.* 23: 389-92.
- Cavassini M, Wenger A, Jaton K, Blanc DS, Bille J (1999). Evaluation of MRSA-Screen, a simple anti-PBP2a slide latex agglutination kit, for rapid detection of methicillin resistance in *Staphylococcus aureus*. *J. Clin. Microbiol.* 37: 1591-1594.
- Chambers HF (1997). Methicillin resistance in staphylococci: molecular and biochemical basis and clinical implications. *Clin. Microbiol. Rev.* 10: 781-91.
- Chambers HF (2001). The changing epidemiology of *Staphylococcus aureus*? *Emerg. Infect. Dis.* 7: 178-182.
- Diekema DJ, BootsMiller DJ, Vaughn TE, Woolson RF, Yankey JW (2004). Antimicrobial resistance trends and outbreak frequency in United States hospitals. *Clin. Infect. Dis.* 38: 78-85.
- El-Farrash MA, Hawas SA, Salama MF, El-Shirbeeney MF, Naguib HA (2003). Phage typing of MRSA isolates from Mansoura University Hospitals. *Egypt. J. Med. Microbiol.* 12: 631-639.
- EL-Hefnawy AMM (1993). Methicillin resistant *Staphylococcus aureus* detection and antibiotic sensitivity test. *Egypt. J. Med. Microbiol.* 2: 311-318.
- Fawzi MA, EL-GhazzawyEF, Mahmoud OA, Ghazal AA, GabAllah AH (2007). Molecular detection of methicillin resistance among staphylococci isolated from clinical specimens. M. Sc. thesis, Alexandria University, Alexandria, Egypt, pp: 66-68.
- Feil EJ, Cooper JE, Grundmann H, Robinson DA, Enright MC (2003). How clonal is *Staphylococcus aureus*? *J. Bacteriol.* 185: 3307-16.
- Felten A, Grandry B, Lagrange PH, Casin I (2002). Evaluation of three techniques for detection of low-level methicillin-resistant *Staphylococcus aureus* (MRSA): a disc diffusion method with cefoxitin and moxalactam, the Vitek 2 system, and the MRSA-Screen latex agglutination test. *J. Clin. Microbiol.* 40: 2766-2771.
- Goossens H (2004). European status of resistance in nosocomial infections. *Chemotherapy*, 51: 177-181.
- Hackbarth CJ, Chambers HF (1989). Methicillin-resistant staphylococci: detection methods and treatment of infections. *Antimicrob. Agents Chemother.* 33: 995-999.
- Hardy KJ, Hawkey PM, Gao F, Oppenheim BA (2004). Methicillin resistant *Staphylococcus aureus* in the critically ill. *Br. J. Anaesth.* 92: 121-130.
- Hartman B, Tomasz A (1981). Altered penicillin-binding proteins in methicillin resistant strains of *Staphylococcus aureus*. *Antimicrob. Agents Chemother.* 19: 726-735.
- Hartman BJ, Tomasz A (1984). Low-affinity penicillin-binding protein associated with  $\beta$ -lactam resistance in *Staphylococcus aureus*. *J. Bacteriol.* 158: 513-516.
- Jevons MP (1961). Celbenin-resistant staphylococci. *Br. Med. J.* 1: 124-125.
- Katayama Y, Ito T, Hiramatsu K (2000). A new class of genetic element, *Staphylococcus* cassette chromosome *mec*, encodes methicillin resistance in *Staphylococcus aureus*. *Antimicrob. Agents Chemother.* 44: 1549-1555.
- Kircher S, Dick N, Ritter V, Sturm K, Warns P (2004). Detection of methicillin-resistant *Staphylococcus aureus* using a new medium, BBL™ CHROMagar™ MRSA, compared to current methods. 104th General Meeting of the American Society for Microbiology, New Orleans, LA.
- Krishnan PU, Miles K, Shetty N (2002). Detection of methicillin and mupirocin resistance in *Staphylococcus aureus* isolates using conventional and molecular methods: a descriptive study from a burns unit with high prevalence of MRSA. *J. Clin. Pathol.* 55: 745-8.
- Nakatomi Y, Sugiyama J (1998). A rapid latex agglutination assay for the detection of penicillin-binding protein 2'. *Microbiol. Immunol.* 42: 739-743.
- National Nosocomial Infections Surveillance (NNIS) System Report, (2004). *Am. J. Infect. Control* 32: 470-485.
- Ontengco DC, Baltazar LA, Santiago RS, Matias RR, Isaac CA (2004). Methicillin-resistant *Staphylococcus aureus* isolates from Filipinopatients (1999-2003). *Phil. J. Microbiol. Infect. Dis.* 33(3): 105-110.
- Perry JD, Davies A, Butterworth LA, Hopley ALJ, Nicholson A (2004). Development and evaluation of a chromogenic agar medium for methicillin-resistant *Staphylococcus aureus*. *J. Clin. Microbiol.* 42: 4519-4523.
- Rayner D (2003). MRSA: an infection control overview. *Nurs. Stand.* 17: 47-53.
- Sakoulas G, Gold HS, Venkataraman L, Degirolami PC, Eliopoulos GM (2001). Methicillin-resistant *Staphylococcus aureus*: Comparison of susceptibility testing methods and analysis of *mecA*-positive susceptible strains. *J. Clin. Microbiol.* 39: 3946-3951.
- Savas L, Duran N, Onlen Y, Savas N, Erayman M (2005). Prospective analysis of antibiotic susceptibility patterns of MRSA in a Turkish University Hospital. *Turk. J. Med. Sci.* 35: 323-327.
- Schmitz FJ, Steiert M, Tichy HV, Hofmann B, Verhoef G (1998). Typing of methicillin resistant *Staphylococcus aureus* isolates from Dusseldorf by six genotypic methods. *J. Med. Microbiol.* 47:341-351.
- Skov R, Smyth R, Clausen M, Larsen AR, Frimodt-Møller N (2003). Evaluation of a cefoxitin 30  $\mu$ g disc on Iso-Sensitest agar for de-

- tection of methicillin-resistant *Staphylococcus aureus*. *J. Clin. Microbiol.* 52: 204-207.
- Skulnick M, Simor AE, Gregson D, Patel M., Small GW (1992). Evaluation of commercial and standard methodology for determination of oxacillin susceptibility in *Staphylococcus aureus*. *J. Clin. Microbiol.*, 30: 1985-1988.
- Smyth RW, Kahlmeter G (2005). Mannitol salt-agar cefoxitin combination as a screening medium for methicillin-resistant *Staphylococcus aureus*. *J. Clin. Microbiol.*, 43: 3797-3799.
- Stoakes L, Reyes R, Daniel J, Lennox G, John MA (2006). Prospective comparison of a new chromogenic medium, MRSASelect, to CHROMagar MRSA and mannitol-salt medium supplemented with oxacillin or cefoxitin for detection of methicillin-resistant *Staphylococcus aureus*. *J. Clin. Microbiol.*, 44: 637-639.
- Swenson JM, Williams PP, Killgore G, O'Hara CM, Tenover FC (2001). Performance of eight methods, including two rapid methods, for detection of oxacillin resistance in a challenge set of *Staphylococcus aureus* organisms. *J. Clin. Microbiol.* 39: 3785-3788.
- Swenson JM, Tenover FC (2005). Results of disc diffusion testing with cefoxitin correlate with presence of *mecA* in *Staphylococcus* spp. *J. Clin. Microbiol.*, 43: 3818-3823.
- Tai PW, Huang CH, Lin QD, Huang YY (2006). Molecular pattern and antimicrobial susceptibility of methicillin resistant *Staphylococcus aureus* isolates at a teaching hospital in Northern Taiwan. *J. Microbiol. Immunol. Infect.* 39: 225-230.
- Vannuffel P, Gigi J, Ezzedine H, Vandercam B, Delmee M (1995). Specific detection of methicillin-resistant *Staphylococcus* Species by multiplex PCR. *J. Clin. Microbiol.*, 33: 2864-2867.
- Van Griethuysen A, Pouw M, Van Leeuwen N, Heck M, Willemse P (1999). Rapid slide latex agglutination test for detection of methicillin resistance in *Staphylococcus aureus*. *J Clin Microbiol*; 37: 2789-2792.
- Velasco D, Tomas MM, Cartelle M, Beceiro A, Perez A (2005). Evaluation of different methods for detecting methicillin (oxacillin) resistance in *Staphylococcus aureus*. *J. Antimicrob. Chemother.*, 55: 379-382.
- Warren DK, Liao RS, Merz LR, Eveland M, Dunne WM (2004). Detection of methicillin-resistant *Staphylococcus aureus* directly from nasal swab specimens by a real-time PCR assay. *J. Clin. Microbiol.*, 42: 5578-5581.
- Zaki SA, Shoala AY, EL-Ghazzawy EF, Hussein AS (1989). Antibiotic sensitivity pattern of hospital strains of *Staphylococcus aureus*, M. Sc. thesis, Alexandria University, Alexandria, Egypt, pp. 51-53.